Triggering by Paf-acether and Adrenaline of Cyclo-oxygenase-independent Platelet Aggregation

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1984 Nov 1

PMID 6439269

Citations 14

Authors

F Fouque

B B Vargaftig

Affiliations

Soon will be listed here.

Abstract

Platelet-activating factor (Paf-acether, 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine) induced full aggregation and a limited release reaction of human platelets in plasma or in blood. Cyclo-oxygenase inhibition with aspirin only reduced aggregation when induced by threshold amounts of Paf-acether, whereas higher concentrations surmounted inhibition whether tested in citrated or in heparinized platelet-rich plasma or blood. Aspirin-induced inhibition of platelet secretion by Paf-acether was insurmountable and independent of the anti-coagulant used. Paf-acether and adrenaline acted synergistically in inducing aggregation in citrate and heparin. Aspirin in vitro or after oral ingestion at doses that suppressed aggregation induced by arachidonic acid alone, failed to reduce significantly the synergized aggregation induced by Paf-acether alone or combined with adrenaline. Twenty-four hours after the oral ingestion of aspirin, when aggregation by arachidonic acid remained blocked, a slight inhibitory activity on the effect of Paf-acether noted 4 h after aspirin, had ceased. This was probably accounted for by the synthesis of thromboxane A2 by newly formed platelets, since the in vitro addition of aspirin, or of the thromboxane/endoperoxide receptor inhibitor 13-azaprostanoic acid caused the 24 h platelets to behave in a manner similar to platelets collected 4 h after aspirin. The alpha 2-adrenoceptor inhibitor, yohimbine, blocked the direct effect of adrenaline as well as its synergism with Paf-acether. Since the synergistic effect of Paf-acether and adrenaline was maintained when thrombin-degranulated platelets were used, and aspirin remained ineffective against it, it is clear that the augmented platelet responsiveness is not accounted for by the platelet release reaction. 6 Paf-acether and adrenaline act synergistically and stimulate platelets by cyclo-oxygenaseindependent mechanisms, which may be relevant in human physiopathological conditions.

Citing Articles

Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Jones R, Wise H, Clark R, Whiting R, Bley K Br J Pharmacol. 2006; 149(1):110-20.

PMID: 16880763 PMC: 1629403. DOI: 10.1038/sj.bjp.0706841.

Paf. A mediator in search of a disease.

Vargaftig B Clin Rev Allergy. 1994; 12(4):419-21.

PMID: 7743465

Proceedings of the British Pharmacological Society. 10th-18th September 1986. Abstracts.

Br J Pharmacol. 1986; 89 Suppl:753P-884P.

PMID: 3779220 PMC: 1916929.

Contribution of ADP to the amplification of primary platelet aggregation by platelet activating factor (PAF): modulatory role of aspirin.

Lauri D, Cerletti C, de Gaetano G Agents Actions. 1986; 17(5-6):506-11.

PMID: 3706054 DOI: 10.1007/BF01965522.

Possible mechanisms of the potentiation of blood-platelet activation by adrenaline.

Bushfield M, Mcnicol A, Macintyre D Biochem J. 1987; 241(3):671-6.

PMID: 3593215 PMC: 1147616. DOI: 10.1042/bj2410671.

References

Vargaftig B, ZIRINIS P . Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2. Nat New Biol. 1973; 244(134):114-6. DOI: 10.1038/newbio244114a0. View

Vargaftig B, Joseph D, Wal F, Marlas G, Chignard M, CHEVANCE L . Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. Eur J Pharmacol. 1983; 92(1-2):57-68. DOI: 10.1016/0014-2999(83)90108-5. View

Reimers H, Kinlough-Rathbone R, Cazenave J, Senyi A, Hirsh J, Packham M . In vitro and in vivo functions of thrombin-treated platelets. Thromb Haemost. 1976; 35(1):151-66. View

Kinlough-Rathbone R, Mustard J, Packham M, Perry D, Reimers H, Cazenave J . Properties of washed human platelets. Thromb Haemost. 1977; 37(2):291-308. View

BYGDEMAN S, TANGEN O . Studies on the mechanism of platelet aggregation and release reaction induced by collagen and adrenaline. Thromb Res. 1977; 11(2):141-8. DOI: 10.1016/0049-3848(77)90032-9. View

Beck E . Effects of heparin on platelet reactivity in citrated plasma. Thromb Haemost. 1977; 38(2):578-80. View

Hsu C, Knapp D, Halushka P . The effects of alpha adrenergic agents on human platelet aggregation. J Pharmacol Exp Ther. 1979; 208(3):366-70. View

Chignard M, Le Couedic J, Tence M, Vargaftig B, Benveniste J . The role of platelet-activating factor in platelet aggregation. Nature. 1979; 279(5716):799-800. DOI: 10.1038/279799a0. View

Cazenave J, Benveniste J, Mustard J . Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest. 1979; 41(3):275-85. View

10.

Le Breton G, Venton D, Enke S, Halushka P . 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979; 76(8):4097-101. PMC: 383985. DOI: 10.1073/pnas.76.8.4097. View

11.

Rao G, Johnson G, White J . Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med. 1980; 5(1):45-58. DOI: 10.1016/0161-4630(80)90090-7. View

12.

Grant J, Scrutton M . Interaction of selective alpha-adrenoceptor agonists and antagonists with human and rabbit blood platelets. Br J Pharmacol. 1980; 71(1):121-34. PMC: 2044410. DOI: 10.1111/j.1476-5381.1980.tb10917.x. View

13.

McManus L, HANAHAN D, Pinckard R . Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981; 67(3):903-6. PMC: 370642. DOI: 10.1172/jci110108. View

14.

Vargaftig B, Chignard M, Benveniste J, Lefort J, Wal F . Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci. 1981; 370:119-37. DOI: 10.1111/j.1749-6632.1981.tb29727.x. View

15.

Marcus A, Safier L, ULLMAN H, Wong K, Broekman M, Weksler B . Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. Blood. 1981; 58(5):1027-31. View

16.

Chesney C, Pifer D, BYERS L, MUIRHEAD E . Effect of platelet-activating factor (PAF) on human platelets. Blood. 1982; 59(3):582-5. View

17.

Rao G, SCHMID H, Reddy K, White J . Human platelet activation by an alkylacetyl analogue of phosphatidylcholine. Biochim Biophys Acta. 1982; 715(2):205-14. DOI: 10.1016/0304-4165(82)90360-9. View

18.

Vargaftig B, Fouque F, Benveniste J, Odiot J . Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. Thromb Res. 1982; 28(4):557-73. DOI: 10.1016/0049-3848(82)90171-2. View

19.

TSIEN W, Ashley C, SHEPPARD H . Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. Thromb Res. 1982; 28(4):587-91. DOI: 10.1016/0049-3848(82)90174-8. View

20.

Dunn F, Soria J, Soria C, Thomaidis A, Tobelem G, Caen J . Fibrinogen binding on human platelets. Influence of different heparins and of pentosane polysulfate. Thromb Res. 1983; 29(2):141-8. DOI: 10.1016/0049-3848(83)90135-4. View